Nomacopan’s dual complement (C5) and leukotriene (LTB4) inhibition blocks several key inflammatory pathways implicated in a range of lung indication characterized by excessive neutrophil activity, and possibly fibrosis, or exacerbations initiated by infections.
Elevation of both C5 and LTB4 have been identified as markers of multiple lung inflammatory conditions including exacerbations in asthma and COPD as well as COVID pneumonia.
Initial work indicates that nomacopan may be deliverable as an inhaled formulation, which would enable a short, self administered treatment focus specifically on patients where a hyper inflammatory state has been triggered.
